Antagonist: Deep Phenotyping and Phenomapping Has Been and Will Continue to Be A Mirage in Understanding the Mechanisms and Tailoring Treatment for HFpEF.

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbvie</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Boehringer Ingelheim; Actavis; Medtronic; 89bio; Altimmune; Alnylam; Ardelyx; Attralus; Biopeutics; Caladrius; Casana; CSL Behring; Imara; Lilly; Moderna; Novartis; Pharmacosmos; Reata; Regeneron; Salamandra</li></ul>